These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 32703453)
1. Growth hormone rescue cerebellar degeneration in SCA3 transgenic mice. Wu S; Liu K; Cheng W; Su S; Lin Y; Lin T; Cheng Y; Chang J; Wu Y; Liu C Biochem Biophys Res Commun; 2020 Aug; 529(2):467-473. PubMed ID: 32703453 [TBL] [Abstract][Full Text] [Related]
2. A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice. Marinina KS; Bezprozvanny IB; Egorova PA Hum Mol Genet; 2024 Aug; 33(16):1406-1419. PubMed ID: 38727562 [TBL] [Abstract][Full Text] [Related]
3. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice. Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949 [TBL] [Abstract][Full Text] [Related]
5. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650 [TBL] [Abstract][Full Text] [Related]
6. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation. Chou AH; Chen YL; Hu SH; Chang YM; Wang HL Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423 [TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. McLoughlin HS; Moore LR; Chopra R; Komlo R; McKenzie M; Blumenstein KG; Zhao H; Kordasiewicz HB; Shakkottai VG; Paulson HL Ann Neurol; 2018 Jul; 84(1):64-77. PubMed ID: 29908063 [TBL] [Abstract][Full Text] [Related]
8. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse. Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860 [TBL] [Abstract][Full Text] [Related]
9. Lee JH; Lin SY; Liu JW; Lin SZ; Harn HJ; Chiou TW Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199295 [TBL] [Abstract][Full Text] [Related]
10. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related]
11. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3. Rajamani K; Liu JW; Wu CH; Chiang IT; You DH; Lin SY; Hsieh DK; Lin SZ; Harn HJ; Chiou TW Neuropharmacology; 2017 May; 117():434-446. PubMed ID: 28223212 [TBL] [Abstract][Full Text] [Related]
12. IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3. Lin YS; Cheng WL; Chang JC; Lin TT; Chao YC; Liu CS Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203722 [TBL] [Abstract][Full Text] [Related]
13. Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells. Konno A; Shuvaev AN; Miyake N; Miyake K; Iizuka A; Matsuura S; Huda F; Nakamura K; Yanagi S; Shimada T; Hirai H Cerebellum; 2014 Feb; 13(1):29-41. PubMed ID: 23955261 [TBL] [Abstract][Full Text] [Related]
15. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684 [TBL] [Abstract][Full Text] [Related]
16. Memory decline, anxiety and depression in the mouse model of spinocerebellar ataxia type 3. Marinina KS; Bezprozvanny IB; Egorova PA Hum Mol Genet; 2024 Feb; 33(4):299-317. PubMed ID: 37862125 [TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555 [TBL] [Abstract][Full Text] [Related]
18. Transcriptomic and Metabolic Network Analysis of Metabolic Reprogramming and IGF-1 Modulation in SCA3 Transgenic Mice. Lin YT; Lin YS; Cheng WL; Chang JC; Chao YC; Liu CS; Wei AC Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360740 [TBL] [Abstract][Full Text] [Related]
19. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119 [TBL] [Abstract][Full Text] [Related]
20. Human Olfactory Ensheathing Cell Transplantation Improves Motor Function in a Mouse Model of Type 3 Spinocerebellar Ataxia. Hsieh J; Liu JW; Harn HJ; Hsueh KW; Rajamani K; Deng YC; Chia CM; Shyu WC; Lin SZ; Chiou TW Cell Transplant; 2017 Oct; 26(10):1611-1621. PubMed ID: 29251109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]